PCSK9 Inhibitors in Cancer Patients Treated with Immune-Checkpoint Inhibitors to Reduce Cardiovascular Events: New Frontiers in Cardioncology
Cancer patients treated with immune checkpoint inhibitors (ICIs) are exposed to a high risk of atherosclerosis and cardiometabolic diseases due to systemic inflammatory conditions and immune-related atheroma destabilization. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key protein invo...
Main Authors: | Vincenzo Quagliariello, Irma Bisceglia, Massimiliano Berretta, Martina Iovine, Maria Laura Canale, Carlo Maurea, Vienna Giordano, Andrea Paccone, Alessandro Inno, Nicola Maurea |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-02-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/15/5/1397 |
Similar Items
-
Combination of <i>Spirulina platensis</i>, <i>Ganoderma lucidum</i> and <i>Moringa oleifera</i> Improves Cardiac Functions and Reduces Pro-Inflammatory Biomarkers in Preclinical Models of Short-Term Doxorubicin-Mediated Cardiotoxicity: New Frontiers in Cardioncology?
by: Vincenzo Quagliariello, et al.
Published: (2022-11-01) -
SARS-CoV-2 Infection and Cardioncology: From Cardiometabolic Risk Factors to Outcomes in Cancer Patients
by: Vincenzo Quagliariello, et al.
Published: (2020-11-01) -
Naturally Occurring PCSK9 Inhibitors
by: Maria Pia Adorni, et al.
Published: (2020-05-01) -
Women at heart: Introducing gender cardio-oncology
by: Maria Laura Canale, et al.
Published: (2022-11-01) -
The Potential Cardiotoxicity of Immune Checkpoint Inhibitors
by: Inbar Nardi Agmon, et al.
Published: (2022-02-01)